Trial · NCT01146652
Results by group909
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 909
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Any TEAE | 1760 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Sarilumab Monotherapy | Any TEAE | 98 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Any TE SAE | 617 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Sarilumab Monotherapy | Any TE SAE | 27 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | PFS-S-associated PTF | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 mg q2w | PFS-S-associated PTF | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 to 150 mg q2w | PFS-S-associated PTF | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | PFS-S-associated FDD | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 mg q2w | PFS-S-associated FDD | 5 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 to 150 mg q2w | PFS-S-associated FDD | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | PFS-S-associated PTC | 0 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 mg q2w | PFS-S-associated PTC | 5 | Participants | |
| Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 to 150 mg q2w | PFS-S-associated PTC | 0 | Participants | |
| Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | 0 | PTF | ||
| Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 mg q2w | 0 | PTF | ||
| Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 to 150 mg q2w | 0 | PTF | ||
| Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | 0 | FDD | ||
| Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 mg q2w | 5 | FDD | ||
| Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System | PFS-S Sarilumab 200 to 150 mg q2w | 0 | FDD | ||
| Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System | PFS-S Sarilumab 150 mg q2w | 0 | PTC |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01146652/results